Though “skepticism” flies on the Street surrounding Tesla’s Model 3 production challenges, Guggenheim’s Rob Cihra bats for the bulls on Tesla’s odds to hit profitability.
Wedbush analyst Michael Pachter maintained a Sell rating on Best Buy Co (NYSE: BBY) today and set a price target of $48. The …
While Valeant shows signs of a rebound, RBC Capital’s Douglas Miehm remains sidelined.
On back of a solid swing for VRX’s rebounding momentum, BTIG’s Tim Chiang sheds light on Q1 earnings and a forthcoming name change.
GBH Insights’ Daniel Ives believes DIS fundamentals are not the star of the show following FQ2 print; it’s all about the Fox acquisition.
Maxim’s Jason McCarthy dives into AMDA’s standout silicon nitride asset sidelined only on capital needs.
Here’s why even bullish analyst Ram Selvaraju of H.C.
H.C.
Oppenheimer’s Leah R. Cann and Canaccord’s John Newman are out with bullish research notes following this biotech giant’s first quarter print.
Cowen’s Chris Shibutani remains confident on AKAO as he angles for plazomicin’s timely approval in cUTI by the end of June.
